BIOTECHNOLOGY

Rhythm’s lead biomarker successfully differentiates between cancer and healthy samples

Finfeed Archived Sep 19, 2019

New antibodies for the key lead biomarker used in Rhythm Biosciences' (ASX: RHY) ColoSTAT® test can successfully differentiate between cancer and healthy samples, and the test has now been optimised.

A healthy six pack in a hot sector: Part 2

Finfeed Archived Sep 11, 2019

The S&P/ASX 200 Healthcare Sector blitzed the rest of the market, increasing 12.7% against the ASX 200 which interestingly by the start of September was already back in positive territory, up 4.5%.

Imagion MRI applications as a new source of revenue

Finfeed Archived Sep 09, 2019

Imagion Biosystems (ASX:IBX) advised the market of early-stage evidence that the technology could have applications in improving magnetic resonance imaging (MRIs).

Immuron shares soar more than 20%

Finfeed Archived Sep 04, 2019

Immuron’s (ASX:IMC) share price has surged on the back of extremely promising clinical results.

Leading investment firm invests in new CSIRO health technology

Finfeed Archived Aug 08, 2019

The estimated present value of benefits from the CSIRO’s work is around $3.2 billion per year, so it's no surprise that the CSIRO and the rather astute BioScience Managers would eventually cross paths.

Rhinomed’s Mute is fastest growing nasal strip in US

Finfeed Archived Jul 11, 2019

Rhinomed Ltd (ASX:RNO), are leaders in airway technology and the developers of the Mute nasal stent, the fastest growing product in the nasal strip category in US based drug stores.

Star Combo surges on Bio-E acquisition

Finfeed Archived Jul 08, 2019

Leading distributor and manufacturer of branded premium health and natural beauty products, Star Combo Pharma Ltd (ASX:S66) has made a transformational acquisition of Bio-e.

Alcidion signs key contract with NSW Health

Finfeed Archived May 20, 2019

Alcidion Group (ASX:ALC) will build and integrate two key components for a proposed national Child Digital Health Record (CDHR), thanks to a new contract with NSW Health.

Digestive health supplement lifts Immuron’s sales

Finfeed Archived Apr 15, 2019

Immuron Limited (ASX:IMC | NASDAQ:IMRN) third quarter sales for its commercially available products, including Travelan®, surged 66%.

Ellume, the digital diagnostics company helping people beat the flu

Finfeed Archived Apr 12, 2019

Dr Sean Parsons is the founder of Ellume, an emerging digital diagnostics company situated in Brisbane that provides smart, self-use diagnostics for the detection and management of pandemic influenza.

Immuron seeking FDA approval for travelers’ diarrhea drug candidate

Finfeed Archived Apr 11, 2019

Australian biopharmaceutical company, Immuron Limited (ASX: IMC |NASDAQ: IMRN), plans to pursue clinical development of IMM-124E, its bovine polyclonal antibody drug candidate to prevent travelers’ diarrhea, through a formal FDA registration pathway.

Genetic Technologies teams up with TGen

Finfeed Archived Apr 08, 2019

Genetic Technologies Ltd (ASX:GTG), a provider of world-leading genetic risk assessment test products, has established an important MoU with TGen, a major player in the US biomedical research industry.

Imugene to present cancer vaccine programs to the American Association for Cancer Research

Finfeed Archived Mar 04, 2019

Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Tanios Bekaii-Saab from the Mayo Clinic will present on its KEYVaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

Biotechnology